Kinetics of Cytomegalovirus Load Decrease in Solid‐Organ Transplant Recipients after Preemptive Therapy with Valganciclovir | Zendy

Frank Mattes | Zendy; Emma Hainsworth | Zendy; A. F. HassanWalker | Zendy; Andrew K. Burroughs | Zendy; P. Sweny | Zendy; Paul Griffiths | Zendy; Vincent C. Emery | Zendy

Open Access

Kinetics of Cytomegalovirus Load Decrease in Solid‐Organ Transplant Recipients after Preemptive Therapy with Valganciclovir

Author(s) -

Frank Mattes,

Emma Hainsworth,

A. F. HassanWalker,

Andrew K. Burroughs,

P. Sweny,

Paul Griffiths,

Vincent C. Emery

Publication year - 2004

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/425905

Subject(s) - valganciclovir , ganciclovir , cytomegalovirus , human cytomegalovirus , medicine , transplantation , organ transplantation , gastroenterology , herpesviridae , virology , virus , viral disease

The availability of valganciclovir (VGCV) has significantly simplified the treatment of human cytomegalovirus (HCMV) infection after solid-organ transplantation. We show that there was no difference in the kinetics of the decrease in HCMV load after preemptive therapy with VGCV in 22 solid-organ transplant recipients (T1/2=2.16 days), compared with that in 23 patients treated with intravenous ganciclovir (GCV) (T(1/2) = 1.73 days; P=.63). Preemptive therapy with VGCV provides control of HCMV replication that is comparable to that achieved with preemptive intravenous therapy with GCV.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research